“The RNA team helped us from inception through our IPO and beyond. They are one of the top firms that I know of at the intersection of valuation, biotech and finance. I’d recommend them for my life science venture-backed company colleagues.”
“The RNA team is responsive and efficient and understands the nuances of valuation as pertains to our sector, and we valued our partnership with them.”
“RNA knows the diagnostics space. From Nanosphere to Biocartis, RNA has been my valuation firm of choice. They are responsive, efficient and I know that they’ll deliver. I’ve been glad to see their success and growth. It’s well deserved.”
Intelligence can create abundance. Only integration decides whether... [read more]
A companion to our peer-reviewed paper in JPMSA... [read more]
[Extended JPMSA article summary] The financial tools most... [read more]
Most founders and CEOs understand bad clients. A... [read more]
It’s Not Always Positive Ask a biotech CEO... [read more]
Unfortunately, this actually happened. I. The Worldview Before... [read more]
Why Biotech Executives and Investors Should Understand the... [read more]
Data-Driven Narrative for Capital Formation in Life Sciences... [read more]
Since 2015, RNA Advisors has provided valuation, transactional... [read more]
Enter your email address below to receive updates from RNA Advisors.
